Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
15 hours ago · Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug Leqembi’s (lecanemab) sales growth is expected to stay gradual ...
News - Biogen
Oct 30, 2024 · Biogen News Releases and Company Statements. Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status.
Biogen to Realign Resources for Alzheimer's Disease Franchise
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area expected to drive near and long-term growth.
Biogen Announces Positive Topline Results from Study of Higher …
Sep 4, 2024 · Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA; Biogen plans to submit for regulatory approval of this investigational dose regimen; Higher dose nusinersen regimen showed statistically significant improvement compared to a prespecified matched sham control group
Samsung Bioepis, Biogen Get European Commission ... - Markets …
20 hours ago · (RTTNews) - Samsung Bioepis Co., Ltd. and Biogen Inc. (BIIB) Monday announced that the European Commission (EC) has approved Opuviz, a biosimilar to Regeneron Pharmaceuticals' Aflibercept. Opuviz ...
Biogen discontinues Alzheimer’s medication Aduhelm - CNN
Jan 31, 2024 · CNN — The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the...
Biogen to Realign Resources for Alzheimer's Disease Franchise
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area...
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs …
Oct 30, 2024 · (Bloomberg) -- Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new Alzheimer’s treatment.
Biogen’s stock rises after E.U. regulator reverses negative view of ...
4 days ago · SPX. -1.36%. Biogen Inc.’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese ...
Biogen stock explodes higher after potential 'mega blockbuster ...
Sep 28, 2022 · Biogen stock (BIIB) is booming amid as Wall Street speculates about a potential profit boom after a promising study detailed the company's new Alzheimer's drug in partnership with Japan’s Eisai.